The online version of this article (doi:10.1007/s00392-015-0934-0) contains supplementary material, which is available to authorized users.
Preclinical investigations have suggested that coating technology is crucial for the efficacy of drug-eluting balloons (DEB). Aim of this study is to compare the antirestenotic efficacy of two paclitaxel DEB with different coatings in the treatment of in-stent restenosis (ISR) by means of a morphological and functional assessment.
In a single center, prospective, non-randomized study, the shellac-paclitaxel coated DIOR, and the urea-paclitaxel coated IN.PACT Falcon were compared in the setting of ISR. Quantitative angiography, fractional flow reserve (FFR), and optical coherence tomography (OCT) were performed at baseline, postprocedure and 6-month follow-up. Main endpoints were QCA, FFR and OCT-based parameters of restenosis.
Forty-five patients were included, 20 (44 %) received treatment with the DIOR and 25 (56 %) with the IN.PACT Falcon. Angiographic and device success were 100 and 90 % for the DIOR, and 100 and 92 % for the IN.PACT Falcon, respectively. After 6-months, in-segment late lumen loss (−0.03 ± 0.43 vs. 0.36 ± 0.48 mm, p = 0.014) and diameter stenosis (30.7 ± 16.2 vs. 41.3 ± 22.6 %, p = 0.083) were lower for the IN.PACT Falcon. FFR distal of the stent was significantly higher in the IN.PACT Falcon group (0.92 ± 0.07 vs. 0.84 ± 0.13, p = 0.029) and in-stent FFR gradient was lower (0.05 ± 0.05 vs. 0.13 ± 0.12, p = 0.002). Between postprocedure and follow-up, a 16 % decrease in neointimal volume was observed for the IN.PACT Falcon, while a 30 % increase was observed for the DIOR (p = 0.006).
The IN.PACT Falcon DEB showed higher antirestenotic efficacy than the DIOR in the treatment of ISR, demonstrating that DEB with an excipient-based coating is not equally effective.
Supplementary material 1 (PDF 221 kb)392_2015_934_MOESM1_ESM.pdf
Tandjung K, Sen H, Lam MK et al (2013) Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. J Am Coll Cardiol 61:2406–2416 CrossRefPubMed
Xu B, Gao R, Wang J et al (2014) A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. J Am Coll Cardiol Interv 7:204–211 CrossRef
Buszman PP, Tellez A, Afari ME et al (2013) Tissue uptake, distribution, and healing response after delivery of paclitaxel via second-generation iopromide-based balloon coating: a comparison with the first-generation technology in the iliofemoral porcine model. J Am Coll Cardiol Interv 6:883–890 CrossRef
Agostoni P, Belkacemi A, Voskuil M, Nathoe HM, Doevendans PA, Stella PR (2013) Serial morphological and functional assessment of drug-eluting balloon for in-stent restenotic lesions: mechanisms of action evaluated with angiography, optical coherence tomography, and fractional flow reserve. J Am Coll Cardiol Interv 6:569–576 CrossRef
Cremers B, Clever Y, Schaffner S, Speck U, Bohm M, Scheller B (2010) Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon. Minerva Cardioangiol 58:583–588 PubMed
Stella PR, Belkacemi A, Waksman R et al (2011) The valentines trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. EuroIntervention 7:705–710 CrossRefPubMed
Tada T, Kadota K, Hosogi S et al (2013) Association between tissue characteristics evaluated with optical coherence tomography and mid-term results after paclitaxel-coated balloon dilatation for in-stent restenosis lesions: a comparison with plain old balloon angioplasty. Eur Heart J Cardiovasc Imaging 15:307–315 CrossRefPubMed
Briguori C, Virmani R, Kolodgie F et al (2012) From bench to bedside: initial experience with the Primus drug-coated balloon catheter. Minerva Cardioangiol 60:507–515 PubMed
- Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis
Pieter R. Stella
Maartje S. Troost
Hendrik M. Nathoe
Pieter A. Doevendans
- Springer Berlin Heidelberg
Neu im Fachgebiet Kardiologie
e.Med Kampagnen-Visual, Mail Icon II